VREX vs LNTH vs GEHC Stock Comparison

Varex Imaging, Lantheus Holdings and GE HealthCare Technologies Prices as of Oct 26, 2026 Peers: Industry group
VREX Varex Imaging Corp
$18.41 -0.2% 1M +53.5% 1Y
Market cap
$776.75M
P/E
35.1x
Revenue (TTM)
$865.00M
Div. yield
–
Diagnostic Equipment Healthcare
LNTH Lantheus Holdings, Inc.
$99.92 +0.2% 1M +78.2% 1Y
Market cap
$6.52B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
7 wins

Head to Head

11 decided of 12

Lantheus Holdings leads on 7 of the 12 questions below (Lantheus Holdings 7, GE HealthCare Technologies 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionVREXLNTHGEHCLeader
Larger companyMarket capitalisation $776.75M $6.52B $32.24B GEHC
Cheaper on earningsLower P/E, profitable companies only 35.1x 23.7x 16.2x GEHC
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.2x 17.3x 14.1x GEHC
Faster revenue growthRevenue growth, trailing twelve months +5.3% +2.3% +6.5% GEHC
More profitableNet margin, trailing twelve months 2.6% 17.7% 9.3% LNTH
Better return on capitalReturn on invested capital 6.9% 12.5% 10.1% LNTH
Less leveragedLower net debt / EBITDA 2.5x -0.1x 2.4x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +53.5% +78.2% -7.9% LNTH
Better 5-year returnAnnualised price return, 5 years -7.0%/yr +34.7%/yr — LNTH
Less volatileAnnualised volatility, 1 year 57.6% 32.4% 34.9% LNTH
Higher overall scoreMean of the five percentile scores vs peers 51/100 80/100 54/100 LNTH

Percentile Scorecard

VREXLNTHGEHC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisVREXLNTHGEHC
Valuation 87 #31 of 228 81 #45 of 228 87 #30 of 228
Growth 23 #170 of 221 63 #83 of 221 23 #171 of 221
Profitability 66 #71 of 208 94 #13 of 208 77 #48 of 208
Financial Health 41 #141 of 239 69 #74 of 239 27 #175 of 239
Shareholder Returns 36 #88 of 137 93 #11 of 137 57 #60 of 137
Overall 51 80 54
  • VREX ranked among 248 companies in Medical Devices and Diagnostics
  • LNTH ranked among 248 companies in Medical Devices and Diagnostics
  • GEHC ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodVREXLNTHGEHCSPY
1 month -0.2%+0.2%+8.0% -0.8%
3 months +67.7%-7.5%+17.8% +3.5%
6 months +44.8%+18.8%+2.1% +7.0%
Year to date +58.0%+50.1%-12.2% +12.2%
1 year +53.5%+78.2%-7.9% +13.0%
3 years +6.4%+49.5%+14.1% +86.3%
3 years, per year +2.1%+14.4%+4.5% +23.1%
5 years -30.3%+343.3%— +68.6%
5 years, per year -7.0%+34.7%— +11.0%
10 years —+1,048.5%— +258.0%
10 years, per year —+27.7%— +13.6%

Risk

MeasureVREXLNTHGEHCSPY
Volatility, 1Y 57.6%32.4%34.9% 12.7%
Downside volatility, 1Y 50.0%27.5%36.0% 12.7%
Beta vs S&P 500, 1Y 1.110.590.68 1.00
Return / volatility, 1Y 0.932.42-0.23 1.02
Max drawdown, 5Y -78.8%-59.5%-37.4% -25.4%
From 52-week high -0.9%-9.9%-18.4% -1.8%
52-week high $18.58$110.94$88.16 $779.14
52-week low $9.32$50.69$59.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleVREXLNTHGEHC
P/E now vs peer median 35.1xmedian 30.6x 23.6xmedian 30.6x 16.4xmedian 30.6x
P/S now vs peer median 0.9xmedian 3.0x 4.2xmedian 3.0x 1.5xmedian 3.0x
EV/EBITDA now vs peer median 10.1xmedian 17.5x 16.4xmedian 17.5x 12.1xmedian 17.5x
P/FCF now vs peer median -38.4xmedian 23.3x 16.8xmedian 23.3x 20.6xmedian 23.3x
P/B now vs peer median 1.5xmedian 2.4x 5.0xmedian 2.4x 3.0xmedian 2.4x
PEG now vs peer median -9.15median 0.87 0.22median 0.87 2.45median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsVREXLNTHGEHC
Revenue $865.00M $1.56B $21.27B
Gross profit $296.90M $936.02M $8.41B
Operating income $72.20M $302.34M $2.73B
Net income $22.40M $275.31M $2.05B
Free cash flow -$20.20M $387.83M $1.58B
R&D $91.40M $173.09M $1.28B
EPS (diluted) $0.52 $4.08 $4.37
Cash & equivalents $99.20M $593.30M $2.11B
Total debt $347.10M $571.05M $10.09B
Shares (diluted) 42.60M 67.52M 454.00M
Enterprise value $308.55M $4.69B $19.30B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricVREXLNTHGEHC
P/E 35.1x 23.6x 16.4x
P/FCF -38.4x 16.8x 20.6x
P/Operating cash flow 68.7x 15.8x 15.5x
P/S 0.9x 4.2x 1.5x
P/B 1.5x 5.0x 3.0x
P/Tangible book 1.6x 10.5x 3.6x
EV/EBITDA 10.1x 16.4x 12.1x
EV/EBIT 14.2x 21.5x 14.8x
EV/Revenue 1.2x 4.2x 1.9x
EV/FCF -50.7x 16.8x 25.6x
EV/Operating cash flow 90.6x 15.7x 19.3x
PEG (3Y EPS CAGR) -9.15 0.22 2.45

Growth

14 metrics
MetricVREXLNTHGEHC
Revenue growth (1Y) 5.3% 2.3% 6.5%
Revenue CAGR (3Y) -1.2% 11.4% 3.8%
Gross profit growth (1Y) 6.1% -3.4% 1.3%
Gross profit CAGR (3Y) 1.2% 16.3% 3.7%
Operating income growth (1Y) 297.8% -30.9% -0.9%
Operating income CAGR (3Y) -2.3% 118.8% 2.9%
Net income growth (1Y) 116.7% 1.6% -11.5%
Net income CAGR (3Y) -9.2% 102.1% 2.9%
EPS growth (1Y) 116.1% 5.8% -10.6%
EPS CAGR (3Y) -3.8% 105.5% 6.7%
Operating cash flow growth (1Y) -81.1% -21.7% 5.1%
Operating cash flow CAGR (3Y) -47.6% 14.5% 0.2%
Free cash flow growth (1Y) -155.5% -10.1% 0.6%
Free cash flow CAGR (3Y) -33.5% 103.0% -2.8%

Profitability

14 metrics
MetricVREXLNTHGEHC
Gross margin 34.3% 60.1% 39.5%
EBITDA margin 11.7% 25.4% 15.7%
Operating margin 8.3% 19.4% 12.9%
Pretax margin 3.2% 23.3% 12.5%
Net margin 2.6% 17.7% 9.3%
FCF margin -2.3% 24.9% 7.4%
Operating cash flow margin 1.3% 26.5% 9.9%
Return on equity 4.5% 21.8% 18.9%
Return on assets 2.1% 11.6% 5.5%
Return on invested capital 6.9% 12.5% 10.1%
Return on capital employed 8.0% 14.8% 9.5%
Asset turnover 0.8x 0.7x 0.6x
Cash conversion (OCF / net income) 0.5x 1.5x 1.0x
Stock comp / revenue 1.7% 5.0% 0.7%

Financial Health

11 metrics
MetricVREXLNTHGEHC
Debt / assets 31.6% 23.6% 27.1%
Debt / equity 0.7x 0.4x 0.9x
Net debt / EBITDA 2.5x -0.1x 2.4x
Debt / FCF -17.2x 1.5x 6.4x
Liabilities / assets 53.6% 45.7% 70.5%
Equity / assets 46.4% 54.3% 29.5%
Interest coverage 1.9x 15.3x 6.4x
Current ratio 3.4x 3.1x 1.3x
Quick ratio 1.3x 2.8x 0.9x
Cash ratio 0.5x 1.8x 0.3x
Altman Z-score 2.28 5.46 1.86

Shareholder Returns

7 metrics
MetricVREXLNTHGEHC
Dividend yield – – 0.2%
Net buyback yield -0.4% 2.9% 1.2%
Shareholder yield -0.4% 2.9% 1.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusVREXLNTHGEHC
Forward P/E 21.2xFY2026 17.3xFY2026 14.1xFY2026
EPS, next fiscal year $0.87FY2026 $5.76FY2026 $5.09FY2026
EPS growth, next FY -3.3%FY2026 -5.3%FY2026 +10.9%FY2026
EPS growth, the year after +14.9% +4.2% -0.4%
Revenue, next fiscal year $829.68MFY2026 $1.57BFY2026 $22.47BFY2026
Revenue growth, next FY -1.8%FY2026 +1.8%FY2026 +8.9%FY2026
Revenue growth, the year after +2.3% +12.7% +7.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersVREXLNTHGEHC
Held by institutions 95.2% 100.0% 87.0%
Institutions holding 186 465 1,221
Change in shares held, QoQ -2.7% +3.4% +1.7%
Institutions buying 98 248 538
Institutions selling 58 142 461
Buyers to sellers 1.69 1.75 1.17

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

VREXLNTHGEHC
VREX 1.00 0.15 0.26
LNTH 0.15 1.00 0.19
GEHC 0.26 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, VREX, LNTH and GEHC?

GE HealthCare Technologies (GEHC) is the largest by market capitalisation: Varex Imaging (VREX) $776.75M, Lantheus Holdings (LNTH) $6.52B, GE HealthCare Technologies (GEHC) $32.24B.

Which stock is cheaper, VREX, LNTH and GEHC?

GE HealthCare Technologies (GEHC) trades on the lowest price-to-earnings ratio (Varex Imaging (VREX) 35.1x, Lantheus Holdings (LNTH) 23.7x, GE HealthCare Technologies (GEHC) 16.2x). On next year's consensus earnings, GE HealthCare Technologies (GEHC) is cheapest (Varex Imaging (VREX) 21.2x, Lantheus Holdings (LNTH) 17.3x, GE HealthCare Technologies (GEHC) 14.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

GE HealthCare Technologies (GEHC) grew revenue fastest over the trailing twelve months: Varex Imaging (VREX) +5.3%, Lantheus Holdings (LNTH) +2.3%, GE HealthCare Technologies (GEHC) +6.5%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Varex Imaging (VREX) 2.6%, Lantheus Holdings (LNTH) 17.7%, GE HealthCare Technologies (GEHC) 9.3%). On return on invested capital, Lantheus Holdings (LNTH) leads (Varex Imaging (VREX) 6.9%, Lantheus Holdings (LNTH) 12.5%, GE HealthCare Technologies (GEHC) 10.1%).

Which stock has performed better?

Over the past year Lantheus Holdings (LNTH) returned the most: Varex Imaging (VREX) +53.5%, Lantheus Holdings (LNTH) +78.2%, GE HealthCare Technologies (GEHC) -7.9%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Varex Imaging (VREX) -7.0%/yr, Lantheus Holdings (LNTH) +34.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Varex Imaging (VREX) 57.6%, Lantheus Holdings (LNTH) 32.4%, GE HealthCare Technologies (GEHC) 34.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, VREX, LNTH and GEHC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.